Mirador Capital Partners LP Cytokinetics Inc Transaction History
Mirador Capital Partners LP
- $536 Million
- Q1 2025
A detailed history of Mirador Capital Partners LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Mirador Capital Partners LP holds 99,125 shares of CYTK stock, worth $3.31 Million. This represents 0.8% of its overall portfolio holdings.
Number of Shares
99,125
Previous 65,636
51.02%
Holding current value
$3.31 Million
Previous $3.09 Million
38.68%
% of portfolio
0.8%
Previous 0.58%
Shares
22 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$490 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$396 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$333 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$267 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$203 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.14B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...